about
Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection--a new frontier?Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes.Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysisProspective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective studyEfficacy of Appropriate Antimicrobial Therapy on the Survival of Patients With Carbapenem Nonsusceptible Klebsiella Pneumoniae Infection: A Multicenter Study in Taiwan.Prior outpatient antibiotic use as predictor for microbial aetiology of community-acquired pneumonia: hospital-based study.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia.The role of carbapenems in initial therapy for serious Gram-negative infections.Morbidity associated with Pseudomonas aeruginosa bloodstream infections.Failure of the MicroScan WalkAway system to detect heteroresistance to carbapenems in a patient with Enterobacter aerogenes bacteremia.Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model.Antimicrobial stewardship programs: methods of operation and suggested outcomes.Rapid identification of pathogens in positive blood culture of patients with sepsis: review and meta-analysis of the performance of the sepsityper kit.Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: utility of a combination antibiogram.[First-line anti-infective treatment in sepsis].Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.Attributable mortality of Acinetobacter baumannii: no longer a controversial issue.Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients.Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.Adherence to standard operating procedures is crucial for intensive care unit survival of elderly patients.Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.Immune response in severe infection: could life-saving drugs be potentially harmful?
P2860
Q27003122-CD3E354A-CA32-46B2-9C40-D8C6B38CB2C7Q33988563-9304E585-C1E4-4F12-B42D-17F0E5215E78Q34064473-D8A5F787-077E-4296-A0DD-F5143BB009DFQ35270405-1E1CA240-2140-4870-990D-CF25E26A3DB2Q35673458-2A69BA6B-1BF6-4D3D-B2B3-12CD8DF0EE27Q35806150-FCA1131B-2DEF-4381-B249-44AF6C4F9CAFQ36165152-FE404597-14E9-4427-AAA6-50832087D633Q36194091-05C440C6-1093-40F2-B8DE-A8BE7A048590Q36478260-25D0BF6C-BE1E-49B9-950F-D5C2DB1AA614Q36517624-8B7B6194-DD13-4E87-8B40-425F6D66F4A5Q36664034-8514B1D2-1A24-495E-B271-EF55F4050D41Q36870904-1B06B6ED-7F00-4B79-94F8-75D0127A91D7Q37169849-79DF75E7-9AA0-4222-99C6-844F381ACD86Q37219943-65644026-A212-4577-AF72-0B79A940F030Q37333683-6EC82A6B-5CA0-4156-BC6C-79286BCBF3B4Q37461442-3533F3CE-239A-4AEE-B0C7-34AA8DB4CDECQ37781944-E56EC835-4142-4802-B913-5722BB8790FFQ37933361-C95D812C-7E73-4C53-AD0D-6F3F67E74E4FQ37965696-F1F99521-48FE-49F5-913F-212EC0F4929FQ38497276-34E27B0C-9203-46FB-941F-1164607E8E37Q39913999-37474AC3-4D64-4F52-8B9B-D92C4D6A5D92Q41689132-6C809938-A4EB-41F1-ADC0-54D7F484B1B7Q41750938-25B4EF0C-4606-48ED-B84E-C2802BC203E7Q41815193-38D48B5F-FC36-40A9-AC9C-980468248494Q42237413-0E86C336-C9E2-4955-AC87-A4766517E6A5Q42790865-88202204-41DE-473E-9E45-E3F631914FA7Q43119954-C391DCDF-331B-4993-9D40-4D4D6FCD3F9DQ47660761-A15BD550-CE48-4249-8965-C59F8A5F3FBAQ51898034-A7408370-DFA6-4094-8ABA-C4AAF4AC4844Q53424473-7D767820-6A39-4591-AAD6-F0FF51643A24Q54651317-95CD6AFE-1C5A-4C88-A9CE-22D31D47A186
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Does antibiotic selection impact patient outcome?
@ast
Does antibiotic selection impact patient outcome?
@en
type
label
Does antibiotic selection impact patient outcome?
@ast
Does antibiotic selection impact patient outcome?
@en
prefLabel
Does antibiotic selection impact patient outcome?
@ast
Does antibiotic selection impact patient outcome?
@en
P2860
P356
P1476
Does antibiotic selection impact patient outcome?
@en
P2093
Vandack Nobre
P2860
P356
10.1086/510075
P407
P577
2006-11-27T00:00:00Z